stockportfolio.pro
Stocks / CHE vs RYTM
CHE vs RYTM
Chemed Corporation and Rhythm Pharmaceuticals, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Chemed Corporation (CHE) | Rhythm Pharmaceuticals, Inc. (RYTM) | |
|---|---|---|
| Market cap | $5.8B | $5.9B |
| Revenue (latest FY) | $2.53B | $189.76M |
| Net income (latest FY) | $265.24M | $-196.54M |
| Revenue growth (5y CAGR) | 4.0% | — |
| Net margin | 10.5% | -103.6% |
| Return on equity | 27.1% | -72.8% |
| P/E ratio | 23.6 | — |
| Dividend yield | 0.5% | — |
| Profitable years (of last 10) | 10 | 0 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CHE — free Open RYTM — freeFrequently asked questions
Which is bigger, CHE or RYTM?
Rhythm Pharmaceuticals, Inc. is larger by market capitalization — $5.9B versus $5.8B.
Which grows faster, CHE or RYTM?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.